Polynovo Ltd (ASX: PNV) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Polynovo Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$1.07 billion
P/E Ratio
2,500.00
Dividend Yield
0.00%
Shares Outstanding
690.23 million
Earnings per share
-0.010
Dividend per share
N/A
Year To Date Return
-23.27%
Earnings Yield
0.04%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Polynovo Ltd (ASX: PNV)
Latest News
Share Gainers
‘Sales records’: 2 ASX 200 shares to ‘build for the future’
Share Gainers
Here are the top 10 ASX 200 shares today
Share Market News
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Share Market News
Here are the top 10 ASX 200 shares today
Share Market News
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Share Market News
5 ASX shares that defined the week
Broker Notes
Brokers name 3 ASX shares to buy now
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Why Estia Health, Graincorp, Novonix, and Polynovo shares are racing higher
Share Gainers
3 ASX All Ords shares rocketing over 10% on big news
Frequently Asked Questions
-
The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was listed on the ASX on 26 November 1998 and is headquartered in Melbourne.
-
No, the company does not historically pay dividends.
PNV ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Polynovo Ltd
PolyNovo Ltd (ASX: PNV) develops and commercialises innovative medical devices using its patented NovoSorb technology.
NovoSorb is a family of biocompatible polymers that are used in the treatment of burns and surgical wounds. They biodegrade into by-products that can be absorbed and excreted by the body. For example, its NovoSorb BTM (Biodegradable Temporising Matrix) can be used to temporarily close a wound and aid the body in generating new tissue.
PolyNovo’s products are sold across Australia and New Zealand, the United States, the United Kingdom, and Europe.
PNV Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 09 Aug 2023 | $1.55 | $0.03 | 1.97% | 677,001 | $1.51 | $1.55 | $1.51 |
| 08 Aug 2023 | $1.53 | $-0.04 | -2.56% | 1,002,879 | $1.57 | $1.58 | $1.52 |
| 07 Aug 2023 | $1.56 | $0.03 | 1.95% | 466,426 | $1.52 | $1.57 | $1.52 |
| 04 Aug 2023 | $1.54 | $0.01 | 0.66% | 1,138,643 | $1.51 | $1.55 | $1.48 |
| 03 Aug 2023 | $1.52 | $-0.05 | -3.18% | 2,293,614 | $1.54 | $1.54 | $1.47 |
| 02 Aug 2023 | $1.57 | $0.00 | 0.00% | 596,663 | $1.57 | $1.58 | $1.55 |
| 01 Aug 2023 | $1.58 | $-0.05 | -3.09% | 995,091 | $1.62 | $1.62 | $1.58 |
| 31 Jul 2023 | $1.62 | $0.04 | 2.53% | 1,103,830 | $1.60 | $1.66 | $1.60 |
| 28 Jul 2023 | $1.58 | $-0.03 | -1.86% | 662,366 | $1.61 | $1.61 | $1.57 |
| 27 Jul 2023 | $1.62 | $0.03 | 1.89% | 1,218,971 | $1.59 | $1.63 | $1.59 |
| 26 Jul 2023 | $1.59 | $0.00 | 0.00% | 652,030 | $1.59 | $1.62 | $1.55 |
| 25 Jul 2023 | $1.58 | $0.00 | 0.00% | 858,463 | $1.58 | $1.59 | $1.55 |
| 24 Jul 2023 | $1.58 | $0.01 | 0.64% | 826,234 | $1.57 | $1.59 | $1.55 |
| 21 Jul 2023 | $1.57 | $-0.03 | -1.87% | 869,762 | $1.61 | $1.61 | $1.57 |
| 20 Jul 2023 | $1.61 | $-0.01 | -0.62% | 907,942 | $1.61 | $1.64 | $1.59 |
| 19 Jul 2023 | $1.61 | $0.05 | 3.19% | 1,316,858 | $1.59 | $1.62 | $1.58 |
| 18 Jul 2023 | $1.57 | $-0.07 | -4.29% | 1,605,233 | $1.63 | $1.66 | $1.56 |
| 17 Jul 2023 | $1.63 | $0.04 | 2.52% | 1,583,693 | $1.59 | $1.64 | $1.57 |
| 14 Jul 2023 | $1.59 | $0.07 | 4.62% | 2,746,785 | $1.54 | $1.60 | $1.52 |
| 13 Jul 2023 | $1.52 | $0.05 | 3.42% | 2,414,253 | $1.49 | $1.52 | $1.48 |
| 12 Jul 2023 | $1.46 | $0.02 | 1.39% | 731,763 | $1.45 | $1.46 | $1.43 |
| 11 Jul 2023 | $1.44 | $0.04 | 2.87% | 2,282,229 | $1.41 | $1.45 | $1.41 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 28 Jun 2023 | Robyn Elliott | Buy | 27 | $39,690 |
On-market trade.
|
| 08 Jun 2023 | David Williams | Buy | 22 | $36,000 |
On-market trade.
|
| 07 Jun 2023 | David Williams | Buy | 14 | $23,448 |
On-market trade.
|
| 22 Mar 2023 | David Williams | Sell | 227 | $465,285 |
On-market trade.
|
| 21 Mar 2023 | David Williams | Sell | 216 | $442,986 |
On-market trade.
|
| 20 Mar 2023 | David Williams | Sell | 305 | $632,556 |
On-market trade.
|
| 17 Mar 2023 | David Williams | Sell | 4 | $8,160,000 |
On-market trade.
|
| 16 Feb 2023 | David Williams | Buy | 1 | $2,229,002 |
Placement.
|
| 16 Feb 2023 | Bruce Rathie | Buy | 200 | $380,000 |
Placement.
|
| 16 Feb 2023 | Robyn Elliott | Buy | 15 | $29,999 |
Placement. As per announcement on 22-02-2023
|
| 16 Feb 2023 | Andrew Lumsden | Buy | 50 | $95,000 |
Placement.
|
| 16 Feb 2023 | Christine Emmanuel | Buy | 140 | $266,000 |
Placement.
|
| 14 Oct 2022 | David Williams | Buy | 42 | $71,708 |
On-market trade.
|
| 13 Oct 2022 | David Williams | Buy | 23 | $40,005 |
On-market trade.
|
| 12 Oct 2022 | David Williams | Buy | 95 | $161,025 |
On-market trade.
|
| 10 Oct 2022 | David Williams | Buy | 115 | $198,152 |
On-market trade.
|
| 10 Oct 2022 | David Williams | Buy | 92 | $156,463 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr David Williams | Non-Executive DirectorNon-Executive Chairman | Feb 2014 |
Mr Williams was appointed as a Non-executive Director on 28 February 2014 and Chairman on 13 March 2014. Mr Williams is an experienced Director and investment banker with a track record in business development as well as in mergers and acquisitions and capital raising.
|
| Mr Bruce Rathie | Non-Executive Director | Feb 2010 |
Mr Rathie was appointed a Director of PolyNovo on 18 February 2010. He is an experienced Company Director with a finance and legal background. He practised as a partner in a legal firm and acted as Senior Corporate Counsel to Bell Resources Limited.
|
| Dr Robyn Elliott | Non-Executive Director | Oct 2019 |
Dr Elliott was appointed a Director of PolyNovo on 28 October 2019. Dr Elliott is currently Global Head, Strategic Portfolio Management at CSL Behring. Dr Elliott previously held Strategic Expansion and Quality Senior Director roles within CSL, was the Managing Director at IDT Australia and commenced her career at DBL Faulding.
|
| Mr Andrew Stuart Lumsden | Non-Executive Director | Jun 2021 |
Mr Lumsden was appointed a Director of PolyNovo on 4 June 2021. He has more than 20 years' experience locally and internationally. Mr Lumsden is currently Chief Executive Officer of Wellcom Worldwide Australasia having previously held the roles of Group Chief Financial Officer and Group Chief Operating Officer.
|
| Mr Leon Hoare | Non-Executive Director | Jan 2016 |
Mr Hoare was appointed a Director of PolyNovo on 27 January 2016. He is currently the Managing Director of Lohmann & Rauscher, Australia & New Zealand (ANZ), a private EU based medical device company. Previously he was Managing Director of Smith & Nephew ANZ (all divisions) until 2015. He served as President of Smith & Nephew's Asia-Pacific Advanced Wound Management (AWM) businesses for 5 years and was a member of the Global Executive Management for the AWM Division.
|
| Ms Christine Emmanuel | Non-Executive Director | May 2020 |
Ms Emmanuel-Donnelly was appointed a Director of PolyNovo on 13 May 2020. She has more than 30 years' local and international experience. She is Vice President of the Board of the Institute of Patent and Trade Mark Attorneys of Australia on Springboard Enterprises Life Sciences Council, is a non-executive director on the board of Medical Developments International and is a member of the Australian Institute of Company Directors.
|
| Mr Jan-Marcel Gielen | Chief Financial OfficerCompany Secretary | Dec 2018 |
-
|
| Mr Swami Raote | Chief Executive Officer | Jul 2022 |
-
|
| Swami Raote | Chief Executive Officer |
-
|
|
| Jan-Marcel Gielen | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 72,331,050 | 10.93% |
| J P Morgan Nominees Australia Pty Limited | 46,707,261 | 7.06% |
| Citicorp Nominees Pty Limited | 24,863,697 | 3.76% |
| Moggs Creek Pty Ltd (Moggs Creek Super A/C) | 17,800,000 | 2.69% |
| BNP Paribas Noms Pty Ltd (Drp) | 12,845,962 | 1.94% |
| Lateral Innovations Pty Ltd (Trust A/C) | 10,924,103 | 1.65% |
| National Nominees Limited | 8,440,944 | 1.28% |
| Mr Anthony Shane Kittel + Mrs Michele Therese Kittel (Kittel Family Super A/C) | 8,040,000 | 1.22% |
| BNP Paribas Nominees Pty Ltd (Ib Au Noms Retailclient Drp) | 6,968,701 | 1.05% |
| Lawn Views Pty Ltd (Angela Williams Family A/C) | 5,692,087 | 0.86% |
| Mr Paul Gerard Brennan | 4,185,095 | 0.63% |
| Ms Simone Maree Beks | 4,185,095 | 0.63% |
| Commonwealth Scientific And Industrial Research Organisation | 4,081,250 | 0.62% |
| Netwealth Investments Limited (Wrap Services A/C) | 3,812,276 | 0.58% |
| Mrs Li Hsien Tsai | 3,276,909 | 0.50% |
| Mr David Kenley | 3,139,855 | 0.47% |
| BNP Paribas Nominees Pty Ltd Acf Clearstream | 3,107,898 | 0.47% |
| Dr Marcus James Dermot Wagstaff + Mrs Lara Kate Wagstaff | 3,056,377 | 0.46% |
| Mr Matthew James Avery | 3,009,397 | 0.45% |
| Mr Paul Lappin + Mrs Siobhan Lyons (Lappin Super Fund A/C) | 2,954,631 | 0.45% |